FDA/FTC's Hot Ticket: Biosimilar Workshop On How To Boost Market, From Education To Lawsuits
Executive Summary
Speakers suggest ways to eliminate barriers to biosimilar uptake, but Janssen pushes back, saying there is need to inform physicians and patients of a biosimilar's interchangeability status. Biosimilar advocates want prescriber incentives, labeling changes, and FDA education on interchangeability.
You may also be interested in...
Biosimilar Competition: Still More Focus On FDA Than FTC
A joint meeting of the US FDA and the FTC on biosimilar competition may have delivered a symbolic message about the need for a ‘level playing field’ in the biologics market – but it did not deliver much in the way of an actionable agenda for antitrust regulators.
US FDA Freezes Inspections And Outside Meetings. Will Review Goal Dates Stay Put?
Sponsors have been asked to switch to teleconferences with FDA staff as the agency prepares for more of its employees to work from home.
Biosimilar Incentives: US Senate Republicans ‘Leery’ Of Out-Of-Pocket, Shared Savings Policies
Senate Finance Committee staffer explains Republicans are inclined to support more moderate approaches in the near term as the 'bigger ideas' for promoting biosimilars evolve.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: